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Abstract
Objectives: Psychotic disorders have large treatment gap in low- and middle-income countries (LMICs) in South-Eastern Europe, 
where up to 45% of affected people do not receive care for their condition. This study will assess the implementation of a generic 
psychosocial intervention called DIALOG+ in mental health care services and its effectiveness at improving patients’ clinical and 
social outcomes. 
Methods: This is a protocol for a multi-country, pragmatic, hybrid effectiveness–implementation, cluster-randomised, clinical trial. 
The trial aims to recruit 80 clinicians and 400 patients across 5 South-Eastern European LMICs: Bosnia and Herzegovina, Kosovo*, 
Montenegro, Republic of North Macedonia and Serbia. Clusters are clinicians working with patients with psychosis, and each clini-
cian will deliver the intervention to five patients. After patient baseline assessments, clinicians will be randomly assigned to either 
the DIALOG+ intervention or treatment as usual, with an allocation ratio of 1:1. The intervention will be delivered six times over 
12 months during routine clinical meetings. TThe primary outcome measure is the quality of life at 12 months [Manchester Short 
Assess¬ment of Quality of Life (MANSA)]; the secondary outcomes include mental health symptoms [Brief Psychiatric Rating 
Scale (BPRS), Clinical Assessment Interview for Negative Symptoms (CAINS), Brief Symptom Inventory (BSI)], satisfaction with 
services [Client Satisfaction Questionnaire (CSQ-8)] and economic costs at 12 months [based on Client Service Receipt Inventory 
(CSRI), EQ-5D-5L and Recovering Quality of Life (ReQOL-10)]. The study will assess the intervention fidelity and the experience 
of clinicians and patients’ about implementing DIALOG+ in real-life mental health care settings. In the health economic assess-
ment, the incremental cost-effectiveness ratio is calculated with effectiveness measured by quality-adjusted life year.  Data will also 
be collected on sustainability and reach to inform guidelines for potentially scaling up and implementing the intervention widely. 
Conclusion: The study is expected to generate new scientific knowledge on the treatment of people with psychosis in health care 
systems with limited resources. The learning from LMICs could potentially help other countries to expand the access to care and 
alleviate the suffering of patients with psychosis and their families.
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INTRODUCTION
Severe mental disorders such as psychotic disorders affect 
3–5% of the population. The symptoms can vary but often 
include hearing voices, not being able to discriminate between 
what is real and what is not, thinking that family or friends 
are part of a conspiracy and social and emotional withdrawal 
(Sadock & Kaplan, 2014). Stigma and discrimination of 
people with psychotic disorders are still common. Their life 
expectancy is lower by 15–20 years compared to the general 
population because of underdiagnosed physical illnesses, 
poor access to health care and suicide (Sadock & Sadock, 
2014). Psychotic disorders have a particularly large treatment 
gap in low- and middle-income countries (LMICs) in South 
Eastern Europe, where up to 45% of affected people do not 
receive care for their condition (WHO, 2008, 2014; McDaid et 
al., 2005). This fosters further social exclusion and inequality 
of this vulnerable group. Health care systems in high-income 
countries provide a combination of care, medication and 
psychosocial interventions, which helps a number of people 
affected by psychotic disorders to find employment and lead a 
productive life. However, LMICs in South Eastern Europe have 
neither the funding nor enough qualified staff to provide such 
specialised services (WHO, 2014; Maric et al., 2019) Therefore, 
there is an urgent need to implement low-cost, easily deliverable 
psychosocial interventions to expand the access to care and 
alleviate the suffering of these patients and their families. 
This study aims to assess the effectiveness and the 
implementation of a psychosocial intervention called 
DIALOG+ in community-based mental health care services 
in five South Eastern European LMICs. The study is designed 
as an effectiveness–implementation hybrid pragmatic trial 
that simultaneously aims to assess the clinical and social 
outcomes of the DIALOG+ intervention relative to treatment 
as usual (TAU), while also assessing the potential utility of the 
implementation strategy in facilitating the implementation of 
DIALOG+ (Curran et al., 2012). As suggested by Curran and 
colleagues, hybrid trials can provide significant benefits such as 
more rapid translational gains, more effective implementation 
strategies and more useful information for decision makers 
(Curran et al., 2012). The DIALOG+ intervention was 
shown effective in the United Kingdom (Priebe et al., 2015); 
however, the uncertainties around the service context in South 
Eastern Europe do not allow its implementation to be simply 
broadened to these countries. The participating countries 
shared similar socioeconomic and political background 
before 1990s, which will facilitate the research project and 
mutual learning across sites. However, their individual 
developments in the post-communist period have led to 
significant differences in the organisation of mental health care 
systems. For that reason, this study will enable us to explore the 
implementation of DIALOG+ within different contexts that are 
potentially representative of other LMICs, thus increasing the 
generalisability and broadening impact of the results. Mental 
health care in the participating countries is still largely hospital 
based because of historical, political, professional and service 
organisation characteristics that impede the development of 
community psychiatry. As indicated by colleagues in Slovenia, 
a high-income country in South-Eastern Europe, these barriers 
are to be addressed through coordinated action involving 
primary care professionals, non-governmental organisations 
with service users and carers, health insurance agencies and 
politicians involved in the planning of health services (Svab 
V and Svab, 2013). We hope that this study will contribute to 
the development of community-based mental health care for 
patients with psychosis in South Eastern Europe.  
DIALOG+ is a technology-assisted intervention based on 
patient-centred communication and solution-focused therapy. 
DIALOG+ was designed to make routine meetings between 
clinicians and patients more therapeutically effective. The 
intervention is available as an app and makes use of a tablet 
computer within routine clinical meetings. In the United 
Kingdom, DIALOG+ has been shown effective in long-term 
patients with psychosis in the community (Priebe et al., 2015). 
It led to reduced clinical symptoms, better quality of life and 
lower treatment costs. DIALOG+ uses already existing clinical 
relationships and does not require establishment of new 
services or referral to other clinicians, so the intervention is 
well suited for health care systems with limited resources. With 
only minimal training (3 hours), a range of clinical staff (e.g. 
nurses, psychologists and psychiatrists) in the United Kingdom 
was able to successfully implement the intervention in routine 
practice (Priebe et al., 2015). As a cost-saving intervention 
that does not rely on any one professional group, it allows for 
affordable management and for expanding patients’ access to 
care. DIALOG+ provides a comprehensive screening of mental, 
physical and social problems and leads to plans for actions in 
all these areas, thus avoiding an inefficient fragmentation of 
care planning. Figure 1 shows key components, proposed 
mechanisms of action and outcomes of DIALOG+ (Omer et 
al., 2016).   
This protocol outlines the design and methods for a multi-
centre, cluster-randomised, controlled trial to evaluate the 
implementation of DIALOG+ in mental health care services 
and its effectiveness at improving patients’ clinical and social 
outcomes. 
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implementation–effectiveness methodology that is not often 
used in psychiatric literature. The work is guided by the 
implementation strategy developed based on the qualitative 
data from the pilot stage and is informed by behavioural theory, 
which is often neglected in the intervention literature. This 
study is the first of its kind conducted in South Eastern Europe 
and one of very few trials in psychosocial mental health care 
provided to patients with psychosis globally. 
PRE-TRIAL WORK 
Before the trial, we conducted a series of activities to inform 
the strategy for implementing DIALOG+ in each country. 
We conducted individual interviews and focus groups with 
all relevant stakeholders (patients, carers, clinicians, service 
providers and policy makers) to understand the local context. 
We also analysed policy documents to better understand local 
regulations in mental health care and their framework for the 
implementation of psychosocial interventions for patients with 
psychosis. Next, five clinician–patient pairs in each country 
met to use DIALOG+ up to three times for 3 months. After 
this pilot study, we organised theoretical domains framework 
(TDF)-based focus groups with patients and clinicians from the 
pilot study (Francis et al., 2012; Cane et al., 2012; Phillips et al., 
2015). These focus groups were conducted to elicit clinicians’ 
and patients’ perceptions about the barriers and facilitators 
of engaging with the DIALOG+ intervention. The TDF is a 
useful and flexible framework for the assessment of barriers 
and targeting resources to influence behaviour change for the 
implementation projects. The TDF consists of 12 domains that 
are proposed to influence behaviour and stimulate behaviour 
change. The discussion was concentrated on how participants 
STUDY AIMS
1) Aim 1 (effectiveness aim) is to explore the clinical 
effectiveness and cost-effectiveness of the DIALOG+ 
intervention (intervention arm) relative to TAU (control arm) 
on patient-level clinical and social outcomes in LMICs in 
South-Eastern Europe. The primary outcome measure is the 
quality of life at 12 months; the secondary outcome measures 
include mental health, satisfaction with services and economic 
costs at 12 months. We hypothesise that the use of DIALOG+ is 
associated with improved quality of life [score on Manchester 
Short Assessment of Quality of Life (MANSA) at 12 months 
(Priebe et al., 1999)], reduced clinical symptoms [scores on Brief 
Psychiatric Rating Scale (BPRS) (Ventura et al., 1993), Clinical 
Assessment Interview for Negative Symptoms (CAINS) (Kring 
et al., 2013) and Brief Symptom Inventory (BSI) (Derogatis, 
1993), and improved satisfaction with services (score on Client 
Satisfaction Questionnaire [CSQ-8])]. We hypothesise that 
overall treatment costs in the intervention arm will be equal 
or lower compared to the control arm. Please find more details 
below under Aim 1.
2) Aim 2 (Implementation aim) is to explore the factors 
associated with successful implementation of DIALOG+ based 
on patient–clinician engagement with and adherence to the 
DIALOG+ intervention (intervention fidelity). We hypothesise 
that clinicians will adhere to the study protocol and deliver the 
DIALOG+ intervention with high fidelity. Please find more 
details below under Aim 2.
This study protocol has the potential to contribute to 
the scientific psychiatric literature by outlining hybrid 
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establishment of new services or referral to other clinicians, so the intervention is well suited for health care 
systems with limited resources. With only minimal training (3 hours), a range of clinical staff (e.g. nurses, 
psychologists and psychiatrists) in the United Kingdom was able to successfully implement the intervention 
in routine practice (Priebe et al., 2015). As a cost-saving intervention that does not rely on any one 
professional group, it allows for affordable management and for expanding patients’ access to care. 
DIALOG+ provides a comprehensive screening of mental, physical and social problems and leads to plans 
for actions in all these areas, thus avoiding an inefficient fragmentation of care planning. Figure 1 shows 
key components, proposed mechanisms of action and outcomes of DIALOG+ (Omer et al., 2016).    
 
Figure 1 - Key components, proposed mechanisms of action and outcomes of DIALOG+  
 
This protocol outlines the design and methods for a multi-centre, cluster-randomised, controlled trial to 
evaluate the implementation of DIALOG+ in mental health care services and its effectiveness at improving 
patients’ clinical and social outcomes.  
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1) Aim 1 (effectiveness aim) is to explore the clinical effectiveness and cost-effectiveness of the DIALOG+ 
intervention (intervention arm) relative to TAU (control arm) on patient-level clinical and social 
outcomes in LMICs in South-Eastern Europe. The primary outcome measure is the quality of life at 12 
months; the secondary outcome measures include mental health, satisfaction with services and economic 
costs at 12 months. We hypothesise that the use of DIALOG+ is associated with improved quality of life 
[score on Manchester Short A sessment of Quality of Life (MANSA) at 12 months (Priebe et al., 1999)] 
and reduced clinical symptoms [scores on BPRS (Ventura et al., 1993), Clinical Assessment Interview 
for Negative Symptoms (CAINS) (Kring et al., 2013) and Brief Symptom Inventory (BSI) (Derogatis, 
1993) and improved satisfaction with services (score on Client Satisfaction Questionnaire [CSQ-8])]. 
We hypothesise that overall treatment costs in the intervention arm is lower compared to the control arm. 
Please find more details below under Aim 1. 
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and Serbia), these services are hospital based. Only services in 
Kosovo* are community based and not linked to psychiatric 
hospitals. In this trial, clusters are clinicians working with 
patients with psychosis in outpatient clinics in the participating 
countries. All eligible clinicians will be invited to participate in 
the study with the goal to recruit a minimum of 16 clinicians per 
country. Inclusion and exclusion criteria are listed in Table 1.
RANDOMISATION, ALLOCATION AND CONCEALMENT
Eligible clinicians will be identified from outpatient psychiatric 
services and consented. Their caseloads will be screened to identify 
patients who met the inclusion criteria. Patients who agree to be 
involved in the study will meet with researchers who will double 
check if patients meet the eligibility criteria and will invite them 
to sign a consent form. Once a patient gives informed consent, 
researchers can proceed to completing the baseline assessment, 
which includes socio-demographic and clinical characteristics, 
subjective quality of life, mental health symptoms, satisfaction 
with services, use of mental health services, and health economic 
assessment. To minimise selection bias within clusters, clinicians 
will be randomised once all patients from their caseload had been 
received and engaged with the intervention and barriers and 
facilitators to engagement. Using the published methods, 
appropriate behaviour change techniques (BCTs) (Michie et 
al., 2013) were identified to address important barriers that 
were assessed for feasibility and usability by researchers in each 
country. On the basis of these steps, an implementation strategy 
was developed iteratively within the team (this preliminary 
research is published separately).
METHODS
This is a multi-country, pragmatic, hybrid effectiveness–
implementation, cluster-randomized, clinical trial. The trail 
aims to recruit 80 clinicians and 400 patients across 5 South-
Eastern European LMICs: Bosnia and Herzegovina, Kosovo*, 
Montenegro, Republic of North Macedonia, and Serbia. The 
coordinating centre is Queen Mary University of London in 
the United Kingdom, where the DIALOG+ intervention was 
developed (Priebe et al., 2015). A cluster-randomisation design 
is used to avoid potential contamination of the practice of 
clinicians when treating patients in both the groups. We will 
test the effectiveness and the cost-effectiveness of DIALOG+ 
for patients with psychosis. The trial will last for 12 months. 
The primary outcome measure is the quality of life at 12 months 
(as measured by MANSA) (Priebe et al., 1999); the secondary 
outcome measures include mental health, satisfaction with 
services and economic costs at 12 months. We hypothesise 
that the use of DIALOG+ is associated with improved 
patient outcomes in these areas. The study will also assess the 
intervention fidelity and clinicians and patients’ experience 
of implementing DIALOG+ in real-life mental health care 
settings. Data will be collected on sustainability and reach to 
inform guidelines for potentially scaling up and implementing 
the intervention widely. The study started with a preparatory 
phase that included exploring socio-cultural context for 
implementing DIALOG+ and developing an implementation 
strategy. Recruited patients will undergo baseline assessments 
before their clinicians are randomised to the intervention 
or standard care. The patients are assessed again at 6 and 12 
months. Figure 2 presents the study flow chart.
ELIGIBILITY CRITERIA
In each participating country, all outpatient psychiatric services 
with caseloads of more than 200 patients with psychosis were 
identified and invited to join the study. A total of 17 services 
were identified. The goal was to include at least two services 
per country. Finally, 11 services were included, 3 in Montenegro 
and 2 in each of the other 4 countries. In 4 countries (Bosnia 
and Herzegovina, Montenegro, Republic of North Macedonia 
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their clinicians are randomised to the intervention or standard care. The patients are assessed again at 6 and 
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Figure 2 – Study flow chart 
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recruited and all baseline assessments were completed. Clinicians 
will be randomised 1:1 to intervention or control. Randomization 
will be conducted by an independent statistician who used 
sequential computer-generated random numbers to determine 
allocation. The randomisation sequence will be created using 
random block sizes of 4 and 6. An unblinded research assistant 
in each country will assign a unique study ID to each clinician 
before the statistician undertakes the randomization of these 
IDs. To prevent an unequal allocation across both groups, the 
participants will be stratified before randomisation on two 
factors: gender (e.g. male vs female) and professional status 
(e.g. psychiatrists vs non-psychiatrists). Baseline data collection 
will be completed before clinicians and the study team were 
made aware of the allocation. The allocation of clusters will be 
concealed from outcome assessors, and clinicians are asked to 
keep their treatment allocation concealed from their colleagues 
and managers.
BLINDING
Owing to the nature of the intervention, clinicians and patients 
in this study cannot be blinded to their allocation to the 
experimental or control group. Researchers who conduct the 
outcome assessments are blinded to the allocation of patients. If 
and when blinding is broken, it is recorded. We will also ensure 
blinding of the data analyst until the entire analysis has been 
completed.
CLINICIANS’ TRAINING
All clinicians randomised to the intervention arm will receive 
face-to-face training to deliver DIALOG+ to patients from a 
member of the local research team. Training materials were 
adapted during the pre-trial work, and appropriate BCTs 
(Michie et al., 2013) were used to classify active ingredients 
of the intervention and to address the identified barriers to 
implementation. The core training lasts for 3 h and enables 
clinicians to implement DIALOG+ in real-world practice 
settings. After the first DIALOG+ session with patients, 
clinicians are offered top-up training sessions that are delivered 
flexibly, tailored to the individual needs. 
OVERVIEW OF THE DIALOG+ INTERVENTION
The intervention group will receive DIALOG+. The 
intervention consists of up to 6 sessions for 12 months (for the 
first 3 months once a month and then every 3 months) during 
routine meetings between patients and clinicians. Each session 
begins with the patient using the tablet to rate their satisfaction 
with eight life domains (mental health, physical health, job 
situation, accommodation, leisure activities, friendships, 
relationship with family/partner and personal safety) and three 
treatment aspects (medication, practical help and meetings 
with professionals). The tablet allows patients to be more 
actively involved in the meeting, with the tablet easily shared 
between the clinician and patient. Each satisfaction item is rated 
on a scale from 1 (‘totally dissatisfied’) to 7 (‘totally satisfied’) 
and followed by a question on whether the patient wants 
additional help with that domain. The ratings are summarised 
on screen, allowing for comparisons with ratings from previous 
meetings. Clinicians are instructed to offer positive feedback 
on any improving or high-scoring domains. The ratings are 
followed by a four-step solution-focused approach to identify 
the patient’s existing resources that can be used to address the 
Table 1. Inclusion and exclusion criteria for clinicians and patients
Clinicians Patients
Inclusion criteria
Having a professional qualification in mental health care 
(e.g. psychiatrists, nurses and psychologists)
More than 6 months’ experience of working in mental 
health care
No plans to leave their post within the study period  
(12 months)
Primary diagnosis of psychosis or related disorder in remission (i.e. ICD-
10 F20-29, F31) (ICD-10, 1990)
Aged 18 years or older
Attending the outpatient clinic or day hospital
History of at least one hospital admission in their lifetime
There should not be plans to leave mental health care services for the 
next 12 months
Capacity to provide informed consent
Exclusion criteria
N/A
Having a diagnosis of organic brain disorders
Having severe cognitive deficits (unable to provide information to study 
instruments). This is based on the clinical judgement
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on medication, psychological support and discussion on other 
aspects of care. At the beginning of the study, clinicians are 
asked not to change their usual approach when working with 
patients in this study. More information on standard outpatient 
mental health care in recruited services in each country is 
available in Table 2. As part of the IMPULSE study, we will 
also audiotape and analyse sessions from the control arm (one 
per clinician) to improve our understanding of the content and 
form of TAU sessions. 
IMPLEMENTATION STRATEGY 
The implementation strategy is a data-driven and theory-
informed document that aims to guide implementation of 
DIALOG+ in this study, if DIALOG+ is shown to be effective, 
to help adapt and scale-up the implementation of DIALOG+ 
to health systems in LMICs in Europe. Such a strategy is 
vital to maximise desired behaviour change and optimise 
implementation of DIALOG+ in LMICs in South-eastern 
Europe. This implementation strategy was designed for use 
by clinicians who deliver DIALOG+, service managers and 
the relevant policy makers. It provides detailed descriptive 
information of each potential barrier and the actions (and 
resources) to overcome it. For example, the pre-trial work 
identified that the most common barrier is clinicians’ perceived 
lack of capability and skills to deliver DIALOG+ to psychotic 
concerns raised. The four steps are Understanding (Why is the 
patient dissatisfied? What nevertheless went well?), Looking 
Forward (What is the best case scenario? What is the smallest 
step forward?), Exploring Options (What can the patient, the 
clinician or others do?) and, finally, Agreeing on Actions (e.g. 
homework and referrals). Each session should last from 30 to 
60 min. It is advisable that first session (or even first 3 sessions) 
last for 60 min to allow enough time for clinicians and patients 
to adapt to using tablets and DIALOG+. After rating domains, 
clinicians and patients need to choose domains for further 
discussion using the four-step solution-focused approach. As a 
general rule, the clinician is advised to select no more than one 
domain in the first session and no more than three domains in 
subsequent sessions, depending on time constraints and focus 
on domains where satisfaction is below 4. Clinicians are asked 
to encourage patients to attend the next session even if they 
did not manage to complete agreed actions. More details can 
be found in DIALOG+ Manual (Priebe et al., 2016). Clinicians 
randomised to the intervention will receive a computer tablet 
with the intervention software (DIALOG+) uploaded. 
CONTROL GROUP
The control group will receive standard care that includes 
routine meetings offering TAU, following the same delivery 
schedule as the intervention arm. This includes consultations 
Table 2. Standard outpatient mental health care in recruited services 
Country Description of routine outpatient mental health care
Bosnia and 
Herzegovina
Hospital-based outpatient services: patients are primarily seen by psychiatrists for every 1–3 months; 
the duration of routine meetings is 15–30 min. Other staffs include nurses, psychologists, social workers, 
occupational therapists and trainees. Interventions offered include medication, psychotherapy and occupational 
therapy.
Kosovo*
Community-based services: patients are primarily seen by nurses one to four times per month, the duration 
of routine meetings is 15–20 min. Psychiatrists see patients once per month or less frequently mainly to review 
medication or provide psychotherapy. Other professionals in services include psychologists, psychotherapists, 
social workers and trainees. Interventions offered include medication, family intervention, occupational therapy 
and home visits.
Republic of 
North Macedonia
Hospital-based services: patients are seen predominately by psychiatrists or psychologists once per month 
or less frequently; the duration of routine meetings is 30 min. Other staffs include nurses, social workers, 
psychotherapists, occupational therapists, pharmacists and psychiatric trainees. Interventions offered include 
medication, psychotherapy, occupational therapy, psychoeducation and supportive psychotherapy.
Montenegro
Hospital-based services: patients are seen predominately by psychiatrists once per month or less frequently; the 
duration of routine meetings 15–45 min. Other staffs include nurses, psychologists, social workers, occupational 
therapists, psychiatric trainees and defectologists. Interventions offered include medication, psychotherapy and 
occupational therapy. 
Serbia
Hospital-based services: patients are seen predominately by psychiatrists and psychologists every 2–3 months; 
the duration of routine meetings is 20–40 min. Other staffs include nurses, social workers, occupational 
therapists and trainees. Interventions offered include medication, psychotherapy, occupational therapy and 
needs-based supportive psychotherapy. 
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Positive Symptom Total. The global indices measure current 
or past level of symptomatology, intensity of symptoms and 
number of reported symptoms, respectively.
-	 Satisfaction with services are assessed using the CSQ-
8 (Attkisson & Greenfield, 2004), which is a self-report 
statement of satisfaction with health and human services. 
The questionnaire has been used in a wide variety of settings 
and contains 8 items, each of the items is rated on a 4-point 
Likert scale. 
-	 Use of mental health services are documented on a 
simplified version of the Client Service Receipt Inventory 
(CSRI) (Beecham, 2001). Information on medication use, 
contact with mental health professionals and any instances 
of hospitalisation in the last 6 months are recorded. 
Research team in each country will provide a list of costs 
for commonly used medicines, health care services and 
inpatient stays.  
-	 Health Economic Assessment will include Recovering 
Quality of Life (ReQoL-10) (Keetharuth et al., 2018), EQ-
5D-5L (Herdman et al, 2011) and the Health Economic 
Assessment Inventory Form. ReQoL-10 is a patient-
reported outcome measure that assesses the quality of life 
for people with various mental health conditions. EQ-5D-
5L is a measure of health-related quality of life for clinical 
and economic assessment.
All questionnaires are administered at baseline, month 6 and 
month 12 in both the groups. The exception is the CAINS, 
which is administered at baseline and month 12. The Health 
Economic Assessment Inventory Form is completed at the end 
of the study by unblinded researchers.  
Process evaluation is conducted to identify how and why 
the intervention was effective or ineffective and the effect 
of context.  Quantitative  data are collected to provide 
implementation feedback, for example, number, duration and 
content of delivered DIALOG+/TAU session. Researchers 
will collect these data after each scheduled session. In-depth 
interviews/focus groups with the participating clinicians, 
patients, service providers and policy makers are conducted at 
the end of the study to explore their experience with DIALOG+ 
intervention.
For more details about the study schedule, refer to Table 3.
DATA ANALYSIS
The study will use both qualitative and quantitative methods. 
The statistical analysis follows guidance for mixed-methods 
research. Descriptive statistics is computed to compare the 
patients. As this barrier could be overcome with sufficient 
training, DIALOG+ training was modified to include proposed 
actions and resources to overcome identified barriers. The 
implementation strategy is updated at the end of the trial based 
on additional findings from the main study and is published 
separately. 
AIM 1: EFFECTIVENESS AND COST-EFFECTIVENESS 
OF DIALOG+
Data are collected using a standardised Case Report Form, 
and each partner site is collecting the same measures for 
all recruited patients. All measures were translated into the 
local languages, and all researchers were trained in patient 
assessments. At baseline, we obtained socio-demographic and 
clinical characteristics including gender, age, ethnicity, highest 
level of education, marital status, employment, mental and 
physical diagnosis, previous psychiatric admissions, prescribed 
medication and received psychosocial interventions. 
Data collection
Study measures include the following: 
-	 Subjective quality of life using the MANSA (Priebe et al., 
1999). The MANSA has been widely used in mental health 
research and contains satisfaction items with 12 life domains 
that are rated by the patient between 1 (most negative score) 
and 7 (most positive score). The mean score of those 12 
items is used to reflect subjective quality of life. 
-	 Mental Health Symptoms are assessed using three 
questionnaires. First, they are observer rated on the 24-item 
Brief Psychiatric Rating Scale (Ventura et al., 1993). Each 
symptom is assessed and rated between 1 (not present) and 
7 (extremely severe) using a scoring guide. In addition, the 
participants are assessed for negative symptoms using the 
CAINS (Kring et al., 2013). The CAINS is an empirically 
developed and evaluated measure of negative symptoms; 
it covers several constructs such as motivation, pleasure, 
social engagement and affective expression. The CAINS 
ratings combine assessments of behavioural engagement in 
relevant activities and reported experiences of motivation 
and emotion, enabling comprehensive assessment of 
negative symptoms. Lastly, BSI (Derogatis, 1993) is 
administered. The BSI consists of 53 items covering 9 
symptom dimensions, such as Somatization, Obsession-
Compulsion, Interpersonal Sensitivity, Depression, 
Anxiety, Hostility, Phobic anxiety, Paranoid ideation and 
Psychoticism, and three global indices of distress, such as 
Global Severity Index, Positive Symptom Distress Index and 
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Table 3. SPIRIT Diagram
Study period
Enrolment Allocation Post-allocation
Time point -t1 0
t1
(6 months)
t2
(12 months)
t3 
(15 months)
Enrolment
Identification of eligible services and clinicians X
Eligibility screen X
Informed consent X
Baseline Assessment X
Allocation X
Clinicians’ training in DIALOG+ X
Interventions
DIALOG+ intervention
Standard care – treatment as usual (TAU)
Assessments
Demographic data X
Subjective quality of life 
MANSA X X X
Mental Health Symptoms
BSI X X X
BPRS X X X
CAINS X X
Satisfaction with services
CSQ X X X
Health Economic Assessment
CSRI X X X
ReQoL-10 X X X
EQ-5D-5L X X X
Health Economic Assessment Inventory X
Evaluation of implementation outcomes
Intervention fidelity
Qualitative interviews/focus groups with patients, clinicians, 
family members X
Sustainability and Reach X
Process evaluation
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HEALTH ECONOMIC ASSESSMENT 
Health Economic Assessment will be conducted from health 
and wider societal perspectives to explore the cost-effectiveness 
of the DIALOG+ intervention for patients with psychotic 
disorders. The evaluation will include the 12-month period 
with data collected at baseline, month 6 and month 12. Data 
for clinical outcomes will be collected for both the control and 
the intervention group. The cost of providing the DIALOG+ 
intervention and TAU will be estimated. Resource use associated 
with delivery of the intervention will be documented by the 
study team over the 12-month period using inventory forms 
developed by a health economist. It includes clinician’s salary, 
costs for documents and materials, and administrative costs. 
The costs for DIALOG+ intervention will also include the one-
off costs such as staff training, and costs of purchasing tablets. 
In addition to the costs of delivery the intervention/treatment, 
data on the use of health and social care services will be collected 
at baseline, month 6, and month 12 by researchers using the 
CSRI (Beecham J, 2001). Unit costs collected from each of the 
five countries will be applied to resource use to estimate patient 
level costs. Costs will be calculated by combining resource use 
of delivering the intervention with respective costs. 
Cost-effectiveness analysis will be conducted to illustrate 
the relation between costs and outcomes for DIALOG+ 
intervention. The cost-effectiveness analyses will compare the 
DIALOG+ intervention with TAU by pooling data from the 
five countries together. Sensitive analysis will be conducted with 
cost-effectiveness analysis on individual country. Furthermore, 
it will be conducted to investigate how uncertainty in the input 
parameters of the cost-effectiveness analyses can affect the 
results. The impact of missing data on the cost-effectiveness 
outcome will be addressed using multiple imputation procedures 
should issues associated with an incomplete dataset arise.
AIM 2: IMPLEMENTATION – CLINICIANS AND 
PATIENTS’ USE OF DIALOG+ AND FACTORS 
ASSOCIATED WITH ITS USE
The study focuses on assessing the intervention fidelity and 
the experience of clinicians and patients about implementing 
DIALOG+ in real-life mental health care settings. Data will also 
be collected on sustainability and reach to inform guidelines for 
scaling up and implementing the intervention widely. 
INTERVENTION FIDELITY 
Intervention fidelity refers to the degree to which an 
intervention is delivered as intended (Caroll et al., 2007). The 
two groups at baseline. Our primary analysis is conducted on 
an intention-to-treat basis, with participants being analysed 
in the group to which they were randomised. The analysis is 
carried out using a repeated measure linear mixed model with 
unstructured covariance matrix to identify whether the groups 
differ in the quality of life at follow-up. The significance level 
is set at 5%. All data analyses are conducted using SPSS. We 
planned to use baseline MANSA as a covariate to account 
for different starting points amongst study patients. Two 
stratifying factors (male/female sex and professional status 
psychiatrist/non-psychiatrist) are considered as covariates. 
Complete case analysis is used as the primary analysis if the 
proportions of missing data are below approximately 5% 
(Jakobsen et al., 2017). The last observation carried forward 
(LOCF) imputation method is used to impute 6-month data 
(if available) into 12-month data. Details about qualitative 
assessments and analysis of qualitative data are provided under 
Aim 2. Quantitative and qualitative data are integrated to 
develop possible explanations for the trial outcomes (O’Cathain 
et al., 2010). In this process, we will first identify potentially 
useful explanatory themes that will be further discussed by the 
research team in order to build more generic explanatory theory. 
The study was powered to look at the effect across the whole 
sample (400 patients). We will perform exploratory analysis of 
differences and similarities between countries included in the 
study hoping that this work could provide additional insights 
into studied topics and possibly generate hypotheses for future 
studies. 
SAMPLE SIZE
Preliminary sample size calculations were based on the data 
from the original DIALOG+ trial for patients with psychosis 
in which the effect size was 0.35 (Priebe et al., 2015). This effect 
size reflects improved the quality of life ratings for 5 of 12 life 
domains in DIALOG+ intervention that indicate a clinically 
and socially relevant improvement. To detect the effect size of 
0.35, the trial would need 260 patients. The number was inflated 
to account for cluster design and 10% dropout of clinicians. As 
mentioned, clusters are clinicians working with patients with 
psychosis, and each clinician will deliver the intervention to 
five patients. The intracluster correlation coefficient (ICC) 
was 0.05, and the design effect (DE) due to cluster randomised 
trial was 1.2 (Kerry et al., 1998). Assuming a standard deviation 
of 1.0, with 80% power at the 5% significance level, the study 
requires a minimum of 36 clinicians in each arm (72 in total) 
at the start of the study. To allow for equal number of clinicians 
per country, we aim to recruit a minimum of 16 clinicians per 
country, 8 in the intervention group and 8 in the control group. 
In total, we aim to recruit 80 clinicians and 400 patients.
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SUSTAINABILITY AND REACH
In order to assess sustainability of the intervention in each 
country, we will conduct up to five individual in-depth 
interviews with service providers (e.g. service manager, clinical 
director, lead nurse) and policy makers. These interviews will 
focus on a) barriers and facilitators on the organisational 
level (infrastructure, clinical leadership engagement, ongoing 
monitoring, policy makers engagement), b) sustainability 
of the intervention (based on the Dynamic Sustainability 
Framework) (Chambers DA et al., 2013); and c) suggestions 
for scaling up and implementing the intervention widely. 
Three months after the last DIALOG+ sessions, we will 
contact all clinicians in each country to collect data on a) 
number of clinicians who continued to use DIALOG+ in their 
practice (intervention arm), b) number of clinicians who are 
delivering DIALOG+ in the control arm; and c) their reasons 
for using or not using DIALOG+ in their practice. Reach will 
be assessed based on number of clinicians and services that 
expressed interest and/or completed training in DIALOG+ 
throughout the study.
DATA COLLECTION
Table 4 offers details on data collected to evaluate intervention 
fidelity, participants’ experience of the intervention and 
sustainability and reach.
DATA ANALYSIS
As mentioned under Aim 1, the study uses both qualitative and 
quantitative methods. Data from focus groups and in-depth 
individual interviews are collected, transcribed and analysed. 
Data from the transcripts are coded in each of the participating 
centres and analysed using the thematic analysis framework 
proposed by Braun and Clarke (2006). Data from audiotaped 
sessions are transcribed and used to assess the adherence to the 
DIALOG+ manual using an operationalised adherence scale. 
Content of DIALOG+ sessions, including identified quality of 
life domains (first part) and agreed actions (second part), is 
collected from tablet computers after each delivered DIALOG+ 
session. Descriptive quantitative analysis determines the 
frequency of identified life domains as well as the frequency of 
actions agreed. Descriptive statistics determines the proportion 
of clinicians who will use the intervention 3 months after 
the study and the mean number of patients receiving the 
intervention. 
evaluation of implementation fidelity is needed because this 
variable may not only moderate the relationship between an 
intervention and its outcomes but its assessment may also 
prevent potentially false conclusions from being drawn about 
an intervention’s effectiveness (Caroll et al., 2007). The study 
uses the framework for intervention fidelity proposed by Carroll 
and colleagues, which includes exposure or dose, adherence to 
an intervention, quality of delivery, participant responsiveness 
and intervention differentiation (Caroll et al., 2007).
A series of activities will be undertaken to assess intervention 
fidelity. Throughout the study unblinded research assistants 
(RAs) will contact clinicians after each scheduled DIALOG+/
TAU session to collect information if the session happened 
as well as duration and content of the delivered session. For 
DIALOG+ sessions RAs will collect data on domains covered 
during the sessions and on agreed actions for patients and 
clinicians. IN addition, clinicians will be asked about any 
problems with delivering the intervention and how the 
problems or obstacles resolved. RAs will provide ongoing 
support and supervision to clinicians. To assess fidelity and 
adherence to study protocol, DIALOG+ manual and training 
materials, as well as quality of delivery, we aim to audiotape 
one DIALOG+ session per clinician. An operationalized 
adherence scale outlining core components of the intervention 
will be used to assess staff competence and the extent to which 
they comply with the study protocol. Content of DIALOG+ 
sessions will be analysed from tablet computers to provide 
additional information and insights. We will also audiotape 
and analyse sessions from the control arm (one per clinician) 
to assess contamination. Data on participant responsiveness 
(e.g. acceptance, perceived usefulness and engagement) and 
intervention differentiation (e.g. how different the active 
intervention is from the control condition) will be collected 
from RAs notes and from end-of-study qualitative interviews/
focus group with study participants. 
CLINICIANS’ AND PATIENTS’ EXPERIENCE OF 
IMPLEMENTING/USING DIALOG+
At the end of the study we will conduct in-depth interviews/
focus groups with all clinicians participating in the intervention 
arm and with up to 15 patients per country who received 
DIALOG+. Purposive sampling will be used to capture different 
patients’ characteristics such as age, gender, and varying levels 
of engagement. The interviews will focus on: a) the experience 
of implementing/using the intervention; b) perceived benefits, 
barriers and facilitators of intervention use; c) participants’ 
engagement and responsiveness; and d) suggested adaptations. 
Data will be used for process evaluation.
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with psychosis have been reported as particularly difficult 
to engage and retain in research trials (Gilbody et al., 2002). 
Despite many similarities, the participating countries differ 
in the provision of standard outpatient mental health care as 
indicated in Table 2, and this may have an impact on the final 
study findings. The trial was not powered to detect differences 
in main outcomes amongst the participating countries; 
however, we plan to conduct an exploratory analysis to gain 
additional insights into main findings. 
Overall, the study has the potential to provide considerable 
insight into whether DIALOG+ is feasible and effective in mental 
health care in South Eastern Europe and the wider LMICs 
context. Some of the challenges shared across LMICs include 
low national mental health care budgets and large treatment gap 
for psychotic disorders as previously mentioned. What is specific 
for countries included in this study and what might make the 
provision of mental health care different and more complex are 
the recent influx of refugees and migrants (after 2015) and the 
long-term psychological and social consequences of the war 
in 1990s. The main study findings are disseminated through 
a variety of mediums, including national and international 
meetings with clinicians, policy makers and researchers, national 
workshops, end-of-study workshops, peer-reviewed journal 
articles, social media platforms and updates on the project’s own 
website (http://impulse.qmul.ac.uk/home/). 
DISCUSSION
This study will test the implementation of a generic psychosocial 
intervention called DIALOG+ in community-based mental 
health care services in five South European countries and its 
effectiveness at improving patients’ quality of life, mental health 
and satisfaction with care. 
The study has several strengths and limitations. To the best of 
our knowledge, this trial is the first of its kind conducted in 
South Eastern Europe and one of very few trials in psychosocial 
mental health care provided to patients with psychosis globally. 
Although most international guidelines suggest combined-
therapy approach including antipsychotic medication, talking 
therapy and family support, most research in this area is still 
focused on advances in pharmacotherapy. This trial is guided 
by the implementation strategy that is initially driven by 
the qualitative data from the pilot stage and is informed by 
behavioural theory, which is often neglected in the intervention 
literature. Further strengths are that patients and their families 
are actively involved in all phases of the study, the outcome 
assessors will be blinded to the allocation of patients and the 
inclusion criteria for patients are wide. The study also has several 
limitations. Clinicians could not be blinded towards their own 
allocation, which raises the possibility of performance bias. The 
dropout rate might be higher than expected because patients 
Table 4. Evaluation of implementation outcomes
Outcome Description Data Source Data collection
Intervention fidelity
Intervention fidelity framework: adherence to an 
intervention, exposure or dose, quality of delivery, 
participant responsiveness and programme 
differentiation (Carroll, 2007)
Staff interviews 
Researchers’ notes 
20% of sessions are audiotaped 
and analysed using content 
analysis 
Content of DIALOG+ sessions is 
analysed from tablet computers
Throughout the 
study, end of the 
study
Clinicians’ 
and patients’ 
experience of using 
DIALOG+
Acceptability and feasibility of the intervention, 
including acceptability of technology (e.g. 
using a computer tablet) to staffs and patients, 
participant responsiveness and engagement with 
the intervention and overall experience with the 
intervention 
Patient and staff interviews/focus 
groups End of the study
Sustainability and 
reach
Organisational level: Sustainability 
(infrastructure, clinical leadership engagement, 
monitoring, factors to promote maintenance) and 
reach (number of additional sites using DIALOG+) 
Individual level: Sustainability [number and 
characteristics of participants (staff and patients) 
who are using DIALOG+ after the competition of 
the active implementation, formative evaluations 
on reasons for using DIALOG+]; Reach (number 
of additional clinicians using DIALOG+) 
Interviews with key informants at 
each site (site champion, medical 
director) based on the Dynamic 
Sustainability Framework 49 
Staff and patient interviews 
Site visits 
Throughout the 
study, end of the 
study 
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signs informed consent, researchers can proceed to completing 
the baseline assessment. Participating patients will receive 
their routine treatment form the mental health care systems 
in their area and/or according their local health insurance 
arrangements. We don’t envisage any risks from participating in 
the study, however some participants taking part in assessment 
and interviews might be upset due to recalling distressing 
personal experiences, mental, physical health and/or social 
functioning problems. In the unexpected event that any patient 
appears highly stressed or upset, the research activity will be 
terminated and a clinician contacted.  
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form prior to their participation in the study. The patients who 
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invite them to sign a consent form. Researchers will explain 
the study to the patient and provide all relevant information, 
including risks, benefits and confidentiality. Once a patient 
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